Kailera Therapeutics, Inc. (KLRA) SEC Filings & Earnings Calls
EquiReason read 9 Kailera Therapeutics, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-12 — Kailera reported Q3 2026 results: R&D spend surged to $101.1M, net loss widened to $111.3M, reflecting post-IPO ramp in clinical development..
Source: SEC EDGAR filings · read by EquiReason
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
12 Aug 202610-QKailera reported Q3 2026 results: R&D spend surged to $101.1M, net loss widened to $111.3M, reflecting post-IPO ramp in clinical development.earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q3-2026 | $1.17B | |
| Research and development expenses · Q3-2026 | $101M | +418% y/y |
| Net loss · Q3-2026 | $-111M | +285% y/y |
Risks flagged
Pre-revenue clinical-stage company with no approved products
“We have not generated any revenues to date and may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.” · word for word
Dependence on Hengrui license agreement and China-related risks
“We depend on our license agreement with, and the comprehensiveness of the intellectual property licensed from, Hengrui. Termination of the Hengrui License Agreement, and issues related to intellectual property we license from Hengrui, would have a material adverse effect on our business.” · word for word
Significant ongoing losses and need for additional capital
“We have incurred significant financial losses since our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future.” · word for word
12 Aug 20268-K · 2.02Positive topline data from Hengrui-conducted Phase 3 T2D trials for ribupatide injection: significant HbA1c reductions (max 2.78%) and non-inferiority vs semaglutide; Phase 2 obesity/PMOS trial showed up to 21.2% weight loss. IND for oral ropen
Risks flagged
Clinical trial failure pressure
“Pipeline dependency on ribupatide; Phase 3 data not expected until 2028.”
26 May 202610-QKailera reported Q1 2026 results: R&D spend surged 600% YoY, net loss widened to $78.9M, and cash position strengthened by $718.8M IPO proceeds.earningsopen
Figures in the filing · each found in the filing text
| Research and development expense · Q1-2026 | $71M | +600% y/y |
| Net loss · Q1-2026 | $-79M | +338% y/y |
| Cash, cash equivalents and marketable securities · 2026-03-31 | $582M |
Risks flagged
Pre-revenue clinical-stage company with no approved products
“Product candidates currently under development will require significant additional research and development efforts, including extensive nonclinical and clinical testing and regulatory approval, prior to commercialization.” · word for word
Dependence on Hengrui license agreement
“our ability to maintain the Hengrui License Agreement underlying our product candidates” · word for word
23 Apr 2026SC 13DBain Capital acquired a 20.27% stake in Kailera Therapeutics, including shares purchased in the IPO, and intends to take an active role in operational and strategic initiatives.open
Risks flagged
Lock-up agreement restricts share sales for 180 days
“the Reporting Person and Mr. Kaplan each agreed, subject to certain exceptions, not to sell or otherwise transfer any shares of the Issuer's Common Stock or securities convertible into or exercisable or exchangeable for, shares of Common Stock for 180 days after the date of the prospectus” · word for word
20 Apr 20268-K · 5.03, 8.01Completed IPO of 44,921,875 shares at $16.00/share, gross proceeds $718.8M. Also amended charter/bylaws post-IPO. Strong positive capital event.open
Figures in the filing · each found in the filing text
| gross IPO proceeds · Q2-2026 | $719M | |
| shares offered · Q2-2026 | 44,921,875 | |
| public offering price per share · Q2-2026 | $16.00 |
Risks flagged
Newly public company with limited operating history and potential governance risks from classified board and exclusive forum provisions
“classified board of directors, exclusive forum provisions, and elimination of stockholder action by written consent”
Kailera Therapeutics, Inc. — questions
- What did Kailera Therapeutics, Inc. file recently?
- 9 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-12 — Kailera reported Q3 2026 results: R&D spend surged to $101.1M, net loss widened to $111.3M, reflecting post-IPO ramp in clinical development.
Every figure on this page comes from Kailera Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.